Immune responses of mice to prime-boost vaccination with the recombinant DNA and Fowlpox virus both expressing Hiv-2 Gag-gp105

Acta Virologica

Volumn 54, Issue 4, 2010, Pages 293-296

  Song, Y ^a   Zhang, L S ^b   Wang, H ^c   Jin, H ^b   Li, C H ^b   Jin, N ^b  

^a TIANJIN UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c JINAN UNIVERSITY   (China)

Author keywords

DNA vaccine; Fowlpox virus; Gag gp105 chimeric protein; HIV 2; Prime boost

Indexed keywords

CHIMERIC PROTEIN; DNA VACCINE; FOWLPOX VIRUS VACCINE; GAG PROTEIN; GLYCOPROTEIN GP 105; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT DNA; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VACCINE; GP105 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 2; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; EXPRESSION VECTOR; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; SPLEEN CELL; VACCINATION; VIRUS RECOMBINANT; ANIMAL; BAGG ALBINO MOUSE; CHICK EMBRYO; DISEASE MODEL; FOWLPOX VIRUS; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOLOGY; VIROLOGY;

FOWLPOX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 2; MUS;

AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CHICK EMBRYO; DISEASE MODELS, ANIMAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; FOWLPOX VIRUS; HIV INFECTIONS; HIV-2; HUMANS; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, DNA;

EID: 79955944907     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: 10.4149/av_2010_04_293     Document Type: Article

References (19)

1. Adamina M, Weber WP, Rosenthal R, Schumacher R, Zajac P, Guller U, Frey DM, Oertli D, Zuber M, Heberer M, Spagnoli GC (2008): Heterologous prime-boost immunotherapy of melanoma patients with Infuenza virosomes, and re-combinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial. Contemp. Clin. Trials 29, 165-181. doi:10.1016/j.cct.2007.07.002
2. Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C, Keefer MC, Kublin JG, Dubey SA, Kierstead LS, Casimiro DR, Shiver JW, Robertson MN, Quirk EK, Mehrotra DV (2010): Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. J. Infect. Dis. 201, 132-141. doi:10.1086/648591
3. Emery S, Kelleher AD, Workman C, Puls RL, Bloch M, Baker D, Anderson J, Hoy J, Ip S, Nalliah K, Ward LD, Law MG, Cooper DA (2007): Infuence of IFNgamma co-expression on the safety and antiviral efcacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy. Hum. Vaccin. 3, 260-267.
4. Herd KA, Wiethe C, Tindle RW (2007): Co-immunisation with DNA encoding RANK/RANKL or 4-1BBL costimula-tory molecules does not enhance efector or memory CTL responses aforded by immunisation with a tumour antigen-encoding DNA vaccine. Vaccine 25, 5209-5219. doi:10.1016/j.vaccine.2007.04.083
5. Kang CY, Luo L, Wainberg MA, Li Y (1999): Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Biol. Chem. 380, 353-364. doi:10.1515/BC.1999.047
6. Li Z, Jin N, Zhang L, Jiang W, Zhang hrs (2004): Humoral and cellular immunogenecity of a DNA vaccine containing HIV-2 chimeric gene gag-gp105 in Balb/c mice. Zhong Guo Bing Du Xue (Virol Sinica) 19, 559-562.
7. Li Z, Jin N, Zhang L, Jiang W (2006): Immune responses induced by HIV-2 recombinant fowlpox virus on mice. Gao Ji Shu Tong Xun (Chinese High Tech Lett) 16, 730-734.
8. McKnight A, Shotton C, Cordell J, Jones I, Simmons G, Clapham PR (1996): Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodefciency virus type 2 SU glycoprotein. J. Virol. 70, 4598-4606.
9. Mölder T, Adojaan M, Kaldma K, Ustav M, Sikut R (2009): Elicitation of broad CTL response against HIV-1 by the DNA vaccine encoding artificial multi-component fusion protein MultiHIV-study in domestic pigs. Vaccine 28, 293-298. doi:10.1016/j.vaccine.2009.10.054
10. Nabel GJ (2001): Challenges and opportunities for development of an AIDS vaccine. Nature 410, 1002-1007. doi:10.1038/35073500
11. Ondondo BO, Yang H, Dong T, di Gleria K, Suttill A, Conlon C, Brown D, Williams P, Rowland-Jones SL, Hanke T, McMichael AJ, Dorrell L (2006): Immunisation with recombinant modifed vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses. Eur. J. Immunol. 36, 2585-2594. doi:10.1002/eji.200636508
12. Promkhatkaew D, Pinyosukhee N, Tongdeejaroen W, Teeka J, Wutthinantiwong P, Leangaramgul P, Sawanpanyalert P, Warachit P (2009): Prime-boost immunization of codon optimized HIV-1 CRF01_AE Gag in BCG with recombinant vaccinia virus elicits MHC class I and II immune responses in mice. Immunol. Invest. 38, 762-779. doi:10.3109/08820130903070544
13. Radaelli A, Bonduelle O, Beggio P, Mahe B, Pozzi E, Elli V, Paganini M, Zanotto C, De Giuli Morghen C, Combadière B (2007): Prime-boost immunization with DNA, recombinant fowlpox virus and VLP (SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells. Vaccine 25, 2128-2138. doi:10.1016/j.vac-cine.2006.11.009
14. Ramsay AJ (1997): DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors. Immunol.Cell Biol. 75, 382-388. doi:10.1038/icb.1997.60
15. Reeves JD, Doms RW (2002): Human immunodefciency virus type 2. J. Gen. Virol. 83, 1253-1265.
16. Watanaveeradej V, Benenson M W, Souza MD, Sirisopana N, Nitayaphan S, Tontichaivanich C, Amphaipit R, Renzullo PO, Brown AE, McNeil JG, Robb ML, Birx DL, Tovanabutra S, Carr JK, McCutchan FE (2006): Molecular epidemiology of HIV Type 1 in preparation for a Phase III prime-boost vaccine trial in Tailand and a new approach to HIV Type 1 genotyping. AIDS Res. Hum. Retroviruses 22, 801-807. doi:10.1089/aid.2006.22.801
17. Wyatt LS, Earl PL, Vogt J, Eller LA, Chandran D, Liu J, Robinson HL, Moss B (2008): Correlation of immunogenicities and in vitro expression levels of recombinant modifed vaccinia virus Ankara HIV vaccines. Vaccine 26, 486-493. doi:10.1016/j.vaccine.2007.11.036
18. Yan Y (2000): Confrmation on the first case of HIV-2 infection in China. Zhong Guo Xing Bing Ai Zi Bing Fang Zhi (Chinese J Prev Control STD AIDS) 1, 5-7.
19. Zhang L, Jin N, Song Y, Wang H, Ma H, Li Z, Jiang W (2007): Construction and characterization of a recombinant fowlpox virus containing HIV-1 multi-epitope-p24 chimeric gene in mice. Sci. China C Life Sci. 50, 212-220. doi:10.1007/s11427-007-0017-1